Rockefeller Capital Management
CAPR icon

Rockefeller Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Rockefeller Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.5K Hold
270
– – ﹤0.01% 4171
2026
Q1 		$8.21K Buy
270
+177
+190% +$4.72K ﹤0.01% 4074
2025
Q4 		$2.68K Hold
93
– – ﹤0.01% 4243
2025
Q3 		$671 Buy
+93
New +$685 ﹤0.01% 4233

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Rockefeller Capital Management's CAPR Position: Q2 2026 in Review

Rockefeller Capital Management held its Capricor Therapeutics (CAPR) position steady in Q2 2026 at 270 shares worth $6.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4171.

Rockefeller Capital Management first reported a position in CAPR in Q3 2025 and has held it in 4 quarters since. The position peaked at $8.21K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Rockefeller Capital Management held 270 shares of Capricor Therapeutics worth $6.5K as of Q2 2026.
  • Rockefeller Capital Management left its Capricor Therapeutics share count unchanged in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4171 holding.
  • Rockefeller Capital Management first reported a position in Capricor Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Capricor Therapeutics position peaked at $8.21K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.